Library — CHDR

Search

Filter

Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial

Selinde S. Wind, Manon A. A. Jansen, Melanie Rijsbergen, Michiel J. van Esdonk, Dimitrios Ziagkos, Wing C. Cheng, Tessa Niemeyer-van der Kolk, John Korsten, Agnieszka Gruszka, Debora Schmitz-Rohmer, David Bonnel, Raphael Legouffe, Florian Barré, Marcel W. Bekkenk, Ellen R. M. de Haas, Koen D. Quint, Melanie Rolli, Henk Johan Streefkerk, Jacobus Burggraaf, Maarten H. Vermeer and Robert Rissmann

Cancers, 2022 Mar

View publication
Cardiac age detected by machine learning applied to the surface ECG of healthy subjects: Creation of a benchmark.

van der Wall HEC, Hassing GJ, Doll RJ, van Westen GJP, Cohen AF, Selder JL, Kemme M, Burggraaf J, Gal P

Journal of electrocardiology, 2022 Mar

View publication
Safety and pharmacokinetics of multiple dosing with inhalable apomorphine (AZ-009), and its efficacy in a randomized crossover study in Parkinson's disease patients.

Thijssen E, den Heijer JM, Puibert D, van Brummelen EMJ, Naranda T, Groeneveld GJ

Parkinsonism & related disorders, 2022 Mar

View publication
The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder

Francis M Dijkstra, Aurora JAE van de Loo, Smedra Abdulahad, Else R Bosma, Mitch Hartog, Hendrikje Huls, Dianne C Kuijper, Esther de Vries, Bhavna Solanki, Jaskaran Singh, Leah Aluisio, Peter Zannikos, Frederik E Stuurman, Gabriël E Jacobs, Joris C Verster

Journal of Psychopharmacology, 2022 Feb

View publication
Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: A placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients.

Moss LM, Algera MH, Dobbins R, Gray F, Strafford S, Heath A, van Velzen M, Heuberger JAAC, Niesters M, Olofsen E, Laffont CM, Dahan A, Groeneveld GJ

PloS one, 2022 Feb; 17(1):e0256752

View publication
De-risking Clinical Trials: The BIAL Phase I Trial in Foresight.

Cohen AF, van Smeden J, Webb DJ

Clinical pharmacology and therapeutics, 2022 Feb; 111(2):362-365

View publication
OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005.

Saghari M, Gal P, Gilbert S, Yateman M, Porter-Brown B, Brennan N, Quaratino S, Wilson R, Grievink HW, Klaassen ES, Bergmann KR, Burggraaf J, van Doorn MBA, Powell J, Moerland M, Rissmann R

Clinical pharmacology and therapeutics, 2022 Jan

View publication
Transcranial magnetic stimulation as biomarker of excitability in drug development: A randomized, double-blind, placebo-controlled, cross-over study.

Ruijs TQ, Heuberger JAAC, de Goede AA, Ziagkos D, Otto ME, Doll RJ, van Putten MJAM, Groeneveld GJ

British journal of clinical pharmacology, 2022 Jan

View publication
Simultaneous measurement of intra-epidermal electric detection thresholds and evoked potentials for observation of nociceptive processing following sleep deprivation

Boudewijn van den Berg, Hemme J. Hijma, Ingrid Koopmans, Robert J. Doll, Rob G. J. A. Zuiker, Geert Jan Groeneveld & Jan R. Buitenweg

Experimental Brain Research , 2022 Jan

View publication

«
1
2
3
4
5
6
7
8
...
88
89
»